| Date | Title | Description |
| 14.05.2021 | MAGENTA THERAPEUTICS, INC.
Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Investors (Form 8-K) | Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
CAMBRIDGE, Mass.-(BUSINESS WIRE)- May 12, 2021-Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel m... |
| 12.05.2021 | MAGENTA THERAPEUTICS, INC.
Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Investors | Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 ... |
| 01.12.2020 | Slone Partners Places Kevin B. Johnson as Senior Vice President of Regulatory Affairs at Inozyme Pharma | “Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless.
SOUTH RIDING, Va. (PRWEB) December 01, 2020
Sl... |
| 13.09.2020 | Акции, стартапы, недвижимость: куда инвестируют Гарвард, Йель, Стэнфорд и другие зарубежные университеты Статьи редакции... | Активы шести университетских фондов — около $178 млрд. Среди их инвестиций компании вроде Google, Facebook и LinkedIn.
13 13 комментариев
8212 просмотров
Фонд Гарварда — $40,9 млрд
Справка
Университет основан в 1636 году, он назван в честь ... |
| 06.05.2020 | AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies | Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies |
| 10.04.2018 | Term Sheet — Tuesday, April 10 | BIKE SHARING WARS
The bike-sharing war is roaring in the United States following its explosive popularity in China and Europe.
Paid Content You can't secure what you can't see From ExtraHop
Jump became the first stationless bicycle service ... |
| 09.04.2018 | Magenta Therapeutics Secures $52 Million in Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the completion of a $52 million Series C fin... |
| 09.04.2018 | Magenta Therapeutics Secures $52 Million in Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the completion of a $52 million Series C fin... |
| 09.04.2018 | Magenta Therapeutics Secures $52M in Series C Financing | Magenta Therapeutics, a Cambridge, MA-based biotechnology company developing novel medicines, completed a $52m Series C financing.
The round was led by Casdin Capital, with participation from new investors EcoR1 Capital, Eventide Asset Mana... |
| 09.04.2018 | Magenta Therapeutics Secures $52M in Series C |
CAMBRIDGE, MA, Biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, closed a $52 million Series C financing.
>> Click here for more funding data on Magenta Therape... |
| 21.02.2018 | Top Pfizer research exec John Davis joins migration to biotech, lands at Magenta as CMO | John Davis
Sue Dillon isn’t the only Big Pharma R&D exec to make news this week after making the switch to biotech. Cambridge, MA-based biotech standout Magenta Therapeutics has just recruited Pfizer vet John Davis as th... |
| 10.11.2017 | Partners HealthCare raises $171M for second innovation fund for healthcare startups (Updated) | Several pharma companies have backed Partners Innovation Fund II such as Astellas Pharma, Eli Lilly, Shang Pharma Corp., and Simcere Pharmaceutical Group. The fund will invest in 15-20 companies, said Roger Kitterman, Vice President of Part... |
| 06.07.2017 | Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks | Two investors that embrace this hybrid approach to healthcare investment also topped the category for investment volume — Alphabet’s investment arm, GV, and Khosla Ventures with seven deals apiece.
GV led or took part in healthcare investme... |
| 02.05.2017 | Magenta Therapeutics Closes $50M Series B Funding | Magenta Therapeutics, a Cambridge, Mass.-based biotechnology company developing therapies to improve and expand the use of curative stem cell transplantation for more patients, completed a $50m Series B financing.
The round was led by GV (f... |
| 02.05.2017 | Magenta Therapeutics Raises $50M Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing therapies to improve and expand the use of curative stem cell transplantation for more patients, today announced rapid progress in advancing the com... |
| 02.05.2017 | Term Sheet — Tuesday, May 2 | PUTTING THE SILICON IN SILICON VALLEY
Today we have another installment in Term Sheet’s series of interviews with dealmakers at the tech industry’s most active acquirers. Cisco is an acquisition machine, having done nearly 200 deals in its ... |
| 16.11.2016 | Term Sheet — Wednesday, November 16 | ET CETERA
Just after 4 p.m. Eastern time yesterday, every single financial news outlet happened upon the exact same four pieces of information:
Paid Content Securing the enterprise without boundaries From ExtraHop
A couple of notes on the n... |
| 16.11.2016 | Magenta Therapeutics Lands $48.5M Series A |
CAMBRIDGE, MA, Magenta Therapeutics announced the completion of a $48.5M Series A financing.
>> Click here for more funding data on Magenta Therapeutics
>> To export Magenta Therapeutics funding data to PDF and Excel, click ... |
| 16.11.2016 | Magenta Therapeutics Completes $48.5M Series A Financing | Magenta Therapeutics, a Cambridge, Mass.-based biotechnology company that develops therapeutics leveraging stem cell biology and bone marrow transplant, completed a $48.5M Series A financing.
The round was led by Third Rock Ventures and Atl... |
| 16.11.2016 | Stem cell startup Magenta launches with $48.5m | In a company news release, Jason Gardner, CEO, president, and co-founder of Magenta Therapeutics said a new wave of stem cell science was ready for commercialization.
“Technical and scientific hurdles have relegated stem cell transplantatio... |
| 16.11.2016 | Magenta Therapeutics Raises $48.5M Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a new biotechnology company developing therapeutics that unlock the power of stem cell biology and bone marrow transplant, today announced the completion of a $48.5M Series A financin... |
| - | Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 3, 2021--
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported fi... |
| - | Stem cell startup Magenta launches with $48.5m | Two top-tier biotech venture firms have collaborated for the first time to create, incubate, and lead a series A financing round for Magenta Therapeutics.
Third Rock Ventures and Atlas Venture summoned a total of $48.5 million for the new C... |
| - | Partners HealthCare raises $171M for second innovation fund for healthcare startups (Updated) | Note: This post has been updated with comments from Roger Kitterman, Vice President of Partners Innovation.
Partners HealthCare System has raised has raised $171 million for a second innovation fund targeting seed stage investments in life ... |
| - | Report: Alphabet venture arm GV, Khosla Ventures claim top spots in healthcare investment ranks | Healthcare investments hit $3.8 billion in the second quarter of 2017, marking a spike in these deals and a milestone for the healthcare industry in general, according to StartUp Health’s half year report. The trend of fewer deals but with ... |
